Clinical Trials
53 trialsNCT05564390 2026-05-26
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01522976 2026-04-30
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03164057 2026-04-23
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02530463 2026-03-05
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03683433 2026-03-05
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02397720 2025-06-08
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05766514 2025-04-22
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
Phase 2 Withdrawn
NCT03931291 2025-03-17
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Phase 2 Completed
NCT02807558 2024-12-13
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Phase 2 Completed
NCT06536959 2024-08-05
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
Phase 2 Recruiting
NCT03493646 2024-05-28
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
Phase 2 Completed
NCT01812252 2024-02-15
ICT-HCT
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT04146038 2023-05-24
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02775903 2023-02-28
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
Phase 2 Completed
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT01168219 2022-08-04
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT04264806 2022-05-20
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT01462578 2021-11-15
RELAZA2
Technische Universität Dresden
Phase 2 Completed
NCT02497404 2021-09-22
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Weill Medical College of Cornell University
Phase 2 Completed
NCT03397173 2021-08-11
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02124174 2021-04-26
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Loyola University
Phase 2 Unknown
NCT01720225 2020-12-24
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02458235 2020-10-12
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
Phase 2 Completed
NCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT00948064 2020-02-24
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02599649 2020-01-14
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02017457 2019-12-10
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
University Hospital of Mont-Godinne
Phase 2 Completed
NCT02447666 2019-07-11
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Celgene
Phase 2 Completed
NCT02469415 2018-10-16
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT02204020 2018-03-30
UPCI 13-165
University of Pittsburgh
Phase 2 Withdrawn
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT00997243 2017-05-10
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00384956 2016-12-12
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
Washington University School of Medicine
Phase 2 Completed
NCT02147873 2016-10-20
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
TetraLogic Pharmaceuticals
Phase 2 Terminated
NCT01541280 2016-03-18
VIDAZA-DLI
Nantes University Hospital
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01338337 2016-01-26
ABRAZA
Asociación Andaluza de HematologÃa y Hemoterapia
Phase 2 Completed
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT01542684 2014-04-30
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01048034 2013-10-29
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Nordic MDS Group
Phase 2 Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00915785 2013-04-24
Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities
King's College London
Phase 2 Completed
NCT00382590 2012-08-07
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed